Ultra-low-dose IL-10-expressing CAR-T cells achieve high efficacy in R/R DLBCL: An update analysis

作者
Yongxian Hu,Mingming Zhang,Min Gao,Yetian Dong,Shan Fu,Jingjing Feng,Ruimin Hong,Guoqing Wei,Duoduo Zhao,Jiazhen Cui,Simao Huang,Tingting Yang,Yilin Li,Xunuo Zhu,Daojun Bai,Jingjing Ren,Chongling Liu,Youjia Li,Qian Chen,Zhan Zhou
出处
期刊:Blood [Elsevier BV]
卷期号:146 (Supplement 1): 2395-2395 被引量:1
标识
DOI:10.1182/blood-2025-2395
摘要

Abstract Context: Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment landscape of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, challenges such as suboptimal durability of complete responses and high relapse rates remain. Preclinical studies have shown that engineering CAR-T cells to secrete IL-10 can enhance their metabolic fitness and antitumor activity (Guo et al., Nat. Immunol. 2021; Zhao et al., Nat. Biotechnol. 2024). To evaluate the clinical safety and efficacy of this strategy, we initiated an open-label, single-arm, investigator-initiated Phase I trial (NCT06120166) of IL-10-expressing CD19 CAR-T cells, designated Meta10-19, in patients with R/R DLBCL. Objective: The primary objective of this phase I trial is to evaluate the safety and tolerability of Meta10-19 in patients with R/R DLBCL. Secondary objectives include assessment of pharmacokinetics and gauging initial efficacy outcomes. Methods: This Phase I trial evaluated the safety and preliminary efficacy of IL-10-expressing CD19 CAR-T cells (Meta10-19) in R/R DLBCL. Autologous whole blood was collected for cell manufacturing. Following lymphodepletion with fludarabine and cyclophosphamide, patients received Meta10-19 infusion at 3 dose levels: 2×103, 5×103, or 2×104 CAR-T cells/kg (corresponding to 1‰ ~ 1% of conventional CAR-T regimens). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded according to Lee 2014 and ASTCT 2019 guidelines, respectively. Adverse events (AEs) were assessed based on CTCAE 5.0 criteria. Results: From November 16, 2023 to October 20, 2024, 12 patients were enrolled, of whom 11 received treatment, and 10 evaluable for efficacy, with 1 succumbing before efficacy evaluation. Among these evaluable patients, the objective responses rate was 100%, comprising 9 CR (90%) and 1 partial response (PR, 10%), suggesting a potent initial antitumor activity even at ultra-low doses. Cytokine release syndrome was observed in 10 patients (Grade 1: 6; Grade 2: 3; Grade 3: 1), while immune effector cell-associated neurotoxicity syndrome occurred in 2 patients (Grade 1: 1; Grade 2: 1). All participants exhibited robust CAR-T cell expansion (average peak: 2437.4 cells/μL), with an increase in serum IL-10 (average peak: 2056.4 pg/mL). Single-cell RNA sequencing (scRNA-seq) further revealed that IL-10 signaling may drive robust expansion of effector CAR-T cells and induce the generation of stem cell-like memory T cells, potentially supporting robust effector response and long-term antitumor immunity. Summary:This IIT clinical trial of Meta10-19 demonstrated promising efficacy at ultra-low cell doses (1‰ of commercial CD19 CAR-T) with robust in vivo expansion and a favorable safety profile. The strong expansion capacity and high complete remission rates underscore the therapeutic potential of Meta10-19. Ongoing studies with extended follow-up and expanded cohorts will be essential to further optimize durability and clinical benefit.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
郭夹心关注了科研通微信公众号
刚刚
1秒前
米米发布了新的文献求助10
1秒前
十一完成签到,获得积分10
1秒前
Ashore完成签到,获得积分10
2秒前
3秒前
慢慢完成签到 ,获得积分10
3秒前
琪qi完成签到,获得积分10
4秒前
RATHER发布了新的文献求助10
5秒前
彭于晏的应助被幸运的成仁采纳,获得10
5秒前
劳小呆发布了新的文献求助10
5秒前
Tengfei753951完成签到 ,获得积分10
5秒前
子岚发布了新的文献求助10
5秒前
6秒前
超级无敌的应助被强健的篮球采纳,获得10
6秒前
东都行发布了新的文献求助10
6秒前
7秒前
7秒前
7秒前
7秒前
8秒前
吃西瓜不吐籽完成签到 ,获得积分10
9秒前
elysia发布了新的文献求助10
9秒前
9秒前
六月雪发布了新的文献求助10
10秒前
所所的应助被lzh采纳,获得10
10秒前
林正心完成签到,获得积分10
11秒前
奇思妙想安德鲁完成签到,获得积分10
12秒前
顾矜的应助被热情的乐荷采纳,获得10
13秒前
9202211125完成签到,获得积分10
13秒前
郭夹心发布了新的文献求助10
13秒前
Akim的应助被一期一会采纳,获得10
13秒前
hmh发布了新的文献求助15
13秒前
水煮电吹风的应助被00hello00采纳,获得10
13秒前
14秒前
drfwjuikesv发布了新的文献求助10
14秒前
15秒前
一米阳光发布了新的文献求助10
15秒前
香蕉觅云的应助被Besttin9799采纳,获得30
15秒前
刘白完成签到,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183667
求助须知:如何正确求助?哪些是违规求助? 9572953
关于积分的说明 21828185
捐赠科研通 7780853
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558251
邀请新用户注册赠送积分活动 2480500